Get started
Author

Pilar Azevedo

Observed names: Azevedo, Pilar, P Azevedo, P. Azevedo, Pilar Azevedo3,4, Pilar T. AZEVEDO
Observed institutions: University of Lisbon, Hospital Pulido Valente, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Unidade Local de Saúde Santa Maria, Clínica Universitária de Pneumologia
ORCID: 0000-0001-7609-200X
Observed ORCID: 0000-0001-7609-200X
OpenAlex ID: A5019952468
Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues
2024 · Pierre-Régis Burgel, Kevin W Southern, et al. · Journal of Cystic Fibrosis · 106
PDF
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials
2023 · Ahmet Z Uluer, Gordon MacGregor, et al. · The Lancet Respiratory Medicine · 88
Serum proteomics signature of Cystic Fibrosis patients: A complementary 2-DE and LC–MS/MS approach
2010 · Nuno Charro, Brian L. Hood, et al. · Journal of Proteomics · 33
The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read‐through therapies in cystic fibrosis
2018 · Luka A. Clarke, Nikhil T. Awatade, et al. · Human Mutation · 30
PDF
SELDI-TOF biomarker signatures for cystic fibrosis, asthma and chronic obstructive pulmonary disease
2009 · Patrícia Gomes-Alves, Margaret Imrie, et al. · Clinical Biochemistry · 30
Recommendations for aetiological diagnosis of bronchiectasis
2016 · A. Amorim, On behalf of the Pulmonology Portuguese Society Bronchiectasis Study Group, et al. · Revista Portuguesa de Pneumologia · 24
Profiling the erythrocyte membrane proteome isolated from patients diagnosed with chronic obstructive pulmonary disease
2012 · Bruno M. Alexandre, Nuno Charro, et al. · Journal of Proteomics · 18
New advances in the therapy of non-cystic fibrosis bronchiectasis
2013 · A. Amorim, F. Gamboa, et al. · Revista Portuguesa de Pneumologia · 14
Burkholderia dolosa phenotypic variation during the decline in lung function of a cystic fibrosis patient during 5.5 years of chronic colonization
2014 · Ana Sílvia Moreira, Carla P. Coutinho, et al. · Journal of Medical Microbiology · 13
Cystic fibrosis – Comparison between patients in paediatric and adult age
2016 · V. Santos, A.V. Cardoso, et al. · Revista Portuguesa de Pneumologia · 7
PDF
Elexacaftor/tezacaftor/ivacaftor—real-world clinical effectiveness and safety. A single-center Portuguese study
2023 · Kelly Lopes1, Catarina Custódio2, et al. · Jornal Brasileiro de Pneumologia · 6
PDF
Personalized Medicine in Cystic Fibrosis: Characterization of Eight Rare CFTR Variants in Intestinal Organoids and Cellular Models
2025 · Violeta Railean, Cláudia S. Rodrigues, et al. · Molecular Diagnosis & Therapy · 5
Isolated ventricular noncompaction: a case report
2009 · João Bento, Filipe Monteiro, et al. · Cases Journal · 3
PDF
Real-Life Adverse Effects of the New Cystic Fibrosis Modulator Therapy
2023 · Amélia Simas Ribeiro, Pilar Azevedo, et al. · European Respiratory Journal · 2
Sweat Chloride Concentration as a Surrogate Marker of CFTR Modulator Therapy Response
2023 · Amélia Simas Ribeiro, Pilar Azevedo, et al. · European Respiratory Journal · 2
Genetic characterization of cystic fibrosis patients in Portugal
2013 · Luisa Pereira, Pilar Azevedo, et al. · European Respiratory Journal · 2
Is there a role for sweat chloride levels as a marker of clinical response to Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis patients?
2023 · Rudi Mauro Pereira Fernandes, Elsa Fragoso, et al. · 1
Chemotherapy Hazards: Anthracycline Extravasation Into Pleural Space
2022 · Almendra, Alexandre, Falcão, Pedro, et al. · PubMed · 1
Iatrogenic Bilateral Pneumothorax Due to Acupuncture
2020 · Filipa Ferro, Cátia Pereira, et al. · Open Respiratory Archives · 1
PDF
Is there a difference in outcome according to etiology of COPD exacerbation in patients admitted to an ICU?
2011 · Filipe Monteiro, Karl Cunha, et al. · European Respiratory Journal · 1
Diagnóstico não Invasivo de Hipertensão Pulmonar e Cor Pulmonale nos Doentes com Doença Pulmonar Crónica Obstrutiva – Importância da Ecocardiografia +
1995 · Pilar Azevedo, Nuno Cardim, et al. · Revista Portuguesa de Pneumologia · 1
PDF
Non-eligibility for highly effective modulator therapy with elexacaftor/tezacaftor/ivacaftor in cystic fibrosis: What about Portugal?
2026 · Elsa Fragoso, Pilar Azevedo, et al. · Pulmonology
PDF
Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey.
2026 · Chiara Premuda, Andrea Gramegna, et al. · European Respiratory Journal
P133 Impact of elexacaftor/tezacaftor/ivacaftor on clinical outcomes and quality of life in children with cystic fibrosis aged 6–11 years in the real-world setting
2025 · JH Rayment, V Daccò, et al. · Thorax
S68 Long-term effects of elexacaftor/tezacaftor/ivacaftor on clinical outcomes and quality of life among adolescents and adults aged 12+ with cystic fibrosis: Interim results from the TRAJECTORY Study
2025 · F Ratjen, C Schwarz, et al. · Thorax
Works count: 45
Citation count: 388
H-index: 9
I10-index: 9
Year
Topic
Type